Twelve HIV care and treatment sites in Rwanda participate in Central Africa IeDEA, including 11 public health facilities and one non-governmental health center. The Rwanda cohort comprises almost 40,000 patients, including 14,800 patients who are currently receiving HIV care. Almost two-thirds of the cohort are female, and approximately 10% were under age 15 at the time of cohort entry.
IeDEA’s work in Rwanda is focused on the following research priorities:
- Exploring pregnancy outcomes in the Option B/B+ era and long-term clinical outcomes among HIV-exposed uninfected children.
- Exploring patient- and health center-level predictors of ART initiation, loss to follow-up and viral suppression under “Treat All” guidelines.
- Assessing changes in renal function among HIV infected adults receiving Tenofovir Disoproxil Fumarate (TDF)-based first-line therapy, the incidence of TDF-induced renal toxicity, and predictors of TDF-induced renal toxicity among HIV infected adults
- Assessing trends in HPV prevalence among HIV+ Rwandan women and assessing the immune response (CD4 cell count) among HIV+ women.
IeDEA’s research in Rwanda is led by principal investigator, Gad Murenzi of Research for Development (RD Rwanda) and the Rwanda Military Referral and Teaching Hospital.